Core Insights - The company is strategically positioned in the next-generation tumor immunotherapy space through its platforms, including the Agonist platform, TCE platform, and ADC, focusing on innovative targets and differentiated pipelines [1] Group 1: Product Development - LBL-024 (PDL1/4-1BB bispecific antibody) has shown historical best data in lung neuroendocrine carcinoma, with excellent efficacy in first-line SCLC and promising preliminary results in NSCLC; it demonstrates a low incidence of ≥3 grade liver enzyme elevation at only 1.3%, indicating superior safety [2] - LBL-034 (GPRC5D/CD3 bispecific antibody) has a 2:1 structure that enhances TAA binding while balancing efficacy and safety; in I/II clinical studies, it achieved an ORR of 77.8% at 400μg/kg and 90.9% at 800μg/kg, comparable to CAR-T efficacy [3] Group 2: Clinical Research and Pipeline - LBL-024 is the first 4-1BB targeted molecule to reach critical clinical stages globally, with ongoing clinical research approved in multiple cancer types including SCLC, BTC, OC, and others, showing promising clinical effects [2] - Other pipeline developments include BDCA2×TACI expected to file IND in the second half of 2025, a CD19/BCMA/CD3 trispecific antibody IND anticipated in Q1 2026, and DLL3 TCE ADC expected to file IND in the first half of 2027 [3] Group 3: Financial Projections - Revenue forecasts for the company are projected at 1.80 billion, 0.94 billion, and 0.10 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 833%, -48%, and -90% [3] - Using a DCF model with a WACC of 8.78% and a perpetual growth rate of 1%, the company's fair stock price is estimated at 101.86 HKD, leading to a fair market capitalization of 20.3 billion HKD [3]

Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of the parent company between 50 million and 65 million yuan for the year 2025, representing an increase of 20.5755 million to 35.5755 million yuan compared to the previous year, which corresponds to a year-on-year growth of 69.93% to 120.90% [2][3] - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 43 million and 58 million yuan, indicating an increase of 20.5359 million to 35.5359 million yuan, with a year-on-year growth of 91.42% to 158.19% [2][3] Group 2: Previous Year Performance - In the previous year, the total profit was 49.0853 million yuan, with a net profit attributable to shareholders of the parent company at 29.4245 million yuan, and a net profit excluding non-recurring gains and losses at 22.4641 million yuan [5] Group 3: Reasons for Performance Increase - The increase in performance is attributed to the company's continuous promotion of refined management and technological upgrades, which have further optimized operational efficiency and cost structure. Additionally, the company has deepened its differentiated competition strategy and increased market expansion efforts, seizing market opportunities to enhance overall profitability [5] Group 4: Asset Impairment Provision - The company plans to recognize an asset impairment provision totaling approximately 9.15 million yuan for the year 2025, which includes a credit impairment loss of 0.65 million yuan and an asset impairment loss of 8.5 million yuan related to inventory [9][10] - The total impairment provision is expected to reduce the net profit attributable to shareholders of the listed company by 9.15 million yuan for the year 2025 [11]

Group 1 - The core point of the article is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has approved the spin-off of its subsidiary Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange [1] - The proposed initial issuance of H-shares will not exceed 25% of the total share capital after issuance, with an option for an additional 15% through an over-allotment [1] - The board believes that the spin-off aligns with regulatory requirements and will help the company focus on its core business, enhance independence, and unlock the valuation potential of its vaccine business segment [1] Group 2 - After the spin-off, Shanghai Fosun Pharmaceutical is expected to maintain control over Fosun Antigen [1] - Fosun Antigen serves as the vaccine business platform for Shanghai Fosun Pharmaceutical, engaging in the research, production, and sales of vaccines [1] - Currently, Fosun Antigen has launched products including human rabies vaccine and influenza virus split vaccine [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of DIZAL PHARMACEUTICAL CO., LTD. 迪哲(江蘇)醫藥股份有限公司 (the "Company") (A joint stock company incorporated in the People's R ...

Group 1 - The core transaction of Te Bao Bio occurred on January 22, with a volume of 91,000 shares and a transaction amount of 6.9533 million yuan, at a price of 76.41 yuan per share [2][4] - In the last three months, Te Bao Bio has recorded a total of 7 block trades, amounting to 57.4718 million yuan [3] - The closing price of Te Bao Bio on the day of the transaction was 76.41 yuan, reflecting a decrease of 2.20%, with a daily turnover rate of 0.52% and a total transaction amount of 163 million yuan [3] Group 2 - The latest margin financing balance for Te Bao Bio is 1.373 billion yuan, with a decrease of 8.1317 million yuan over the past five days, representing a decline of 0.59% [4] - The company, Xiamen Te Bao Bioengineering Co., Ltd., was established on August 7, 1996, with a registered capital of 4.0818948 billion yuan [4]

证券日报网讯 1月22日，利德曼在互动平台回答投资者提问时表示，截至2026年1月20日收盘，公司股 东人数为31371户。 （文章来源：证券日报） ...

北京商报讯1月22日，*ST赛隆发布公告称，公司于2025年12月23日召开了第四届董事会第十九次会 议，审议通过了《关于对全资子公司以债转股方式进行增资并公开挂牌转让其股权的议案》 。公司拟 委托湖南省联合产权交易所有限公司挂牌转让所持有的全资子公司湖南赛隆生物制药有限公司100%股 权，首次挂牌底价根据北京坤元至诚资产评估有限公司的评估结果确定为人民币8695万元，首次挂牌公 告起止日期为2026年1月23日—2月12日。 （文章来源：北京商报） ...

（编辑 丛可心） 证券日报网讯 1月22日，上海莱士在互动平台回答投资者提问时表示，按照相关规则，权益分派事项应 当在上市公司股东会审议通过利润分配方案后两个月内完成。公司于2025年12月15日召开的2025年第三 次临时股东会，会上审议通过了《2025年前三季度利润分配方案》，公司将按照前述规则要求及时完成 权益分派事项，具体分派时间以公司公告为准。 ...

证券日报网讯1月22日，上海莱士（002252）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总户数为110824户。 ...

Core Viewpoint - The announcement by Vili Zhibo-B (09887) regarding the orphan drug designation for LBL-024 (Opalizumab) for the treatment of pulmonary neuroendocrine carcinoma marks a significant milestone in its global development process, following a similar designation from the FDA [1] Group 1 - The European Commission (EC) granted orphan drug designation for LBL-024 on January 9, 2026, which is the second such designation after receiving FDA recognition [1] - Orphan drugs are defined by the EC as those intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating conditions with a prevalence of less than 5 in 10,000 in the EU [2] Group 2 - The orphan drug designation provides several key incentives, including scientific advice from the European Medicines Agency (EMA) on various aspects of research design [2] - It grants a 10-year market exclusivity period in the EU from the date of marketing authorization, preventing other companies from approving similar drugs for the same indication during this time [2] - Additional benefits include fee reductions for regulatory processes and potential funding from the EC and Horizon Europe, as well as extra incentives for micro, small, and medium-sized enterprises [2]